In Brief: Ex vivo autologous cell products
Executive Summary
Ex vivo autologous cell products: FDA public hearing on products comprised of living autologous cells manipulated ex vivo and intended for implantation for structural repair or reconstruction will take place at the Gaithersburg, Md. Hilton beginning at 9 a.m. on Nov. 16-17 ("The Pink Sheet" July 17, T&G-12)...